FDA Panel Slams Endologix Response to Stent-Graft Safety Issues FDA Panel Slams Endologix Response to Stent-Graft Safety Issues

The company argued to skeptical advisors that upgrades to its AAA-repair system have already cut any potential endoleak risk, a long-running concern and the object of repeated alerts and recalls.Medscape Medical News
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Source Type: news